Circulation, Vol 85, 997-1002, Copyright © 1992 by American Heart Association
C Risoe, S Simonsen, K Rootwelt, S Sire and OA Smiseth
BACKGROUND. This study investigates the effects of sodium nitroprusside on
regional vascular capacitance in eight patients with severe congestive
heart failure (New York Heart Association class IV) and pulmonary
hypertension. METHODS AND RESULTS. Regional relative blood volumes in the
splanchnic and pulmonary region were determined by equilibrium blood pool
scintigraphy. Hepatic venous wedge pressure and the mean of pulmonary
artery and pulmonary capillary wedge pressure were used to represent the
distending pressures of the splanchnic and pulmonary capacitance vessels,
respectively. The dose of sodium nitroprusside was increased stepwise until
systolic pulmonary artery pressure decreased below 50 mm Hg. This caused
reductions in mean aortic pressure from 89 +/- 5 to 66 +/- 3 mm Hg (p less
than 0.005), in pulmonary capillary wedge pressure from 31 +/- 1 to 16 +/-
2 mm Hg (p less than 0.001), and in hepatic venous wedge pressure from 10.0
+/- 1.0 to 5.9 +/- 0.6 mm Hg (p less than 0.005). Intestinal blood volume
increased by 26 +/- 7% (p less than 0.005), whereas hepatic blood volume
decreased by 9 +/- 3% (p less than 0.02). Pulmonary blood volume was
unchanged. Analysis of intestinal and pulmonary vascular pressure- volume
relations showed larger or equal blood volumes contained at lower
distending pressures, indicating that sodium nitroprusside reduced smooth
muscle tone of the capacitance vessels in these regions. The reduction of
hepatic blood volume was compatible with passive expulsion of blood
subsequent to reduced venous pressure. There was no change in the count
rate from the spleen. CONCLUSIONS. Nitroprusside reduced venous pressure in
patients with congestive heart failure by active relaxation of intestinal
and pulmonary capacitance vessels. Hepatic vascular volume was probably
reduced by a passive mechanism.
ARTICLES
Nitroprusside and regional vascular capacitance in patients with severe congestive heart failure
Medical Department B, Rikshospitalet, Oslo, Norway.
This article has been cited by other articles:
![]() |
S. Capomolla, O. Febo, C. Opasich, G. Guazzotti, A. Caporotondi, M. T. La Rovere, M. Gnemmi, A. Mortara, M. Vona, G. D. Pinna, et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome Eur J Heart Fail, October 1, 2001; 3(5): 601 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kjekshus, C. Risoe, T. Scholz, and O. A. Smiseth Regulation of Hepatic Vascular Volume : Contributions From Active and Passive Mechanisms During Catecholamine and Sodium Nitroprusside Infusion Circulation, December 16, 1997; 96(12): 4415 - 4423. [Abstract] [Full Text] |
||||
![]() |
S. Y. Wang, D. E. Manyari, N. Scott-Douglas, O. A. Smiseth, E. R. Smith, and J. V. Tyberg Splanchnic Venous Pressure–Volume Relation During Experimental Acute Ischemic Heart Failure : Differential Effects of Hydralazine, Enalaprilat, and Nitroglycerin Circulation, February 15, 1995; 91(4): 1205 - 1212. [Abstract] [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1992 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |